Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies. Co. is designing new treatments for various forms of cancer, including both hematological cancers and solid tumors. Co.'s programs include: BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen; BCMA GoCAR-NK, which targets B cell maturation antigen that is expressed by various myeloma cells; and Rivo-cel, which is for the treatment of hematologic malignancies and inherited blood disorders. The BLCM stock yearly return is shown above.
The yearly return on the BLCM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BLCM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|